They are different things with different effects. PPAR gamma is for the physical effects of addiction to nicotine and opiates. 527 is for cravings, mental addiction and compulsion.
They were not in charge of the Phase 2 because it was sponsored. It was a hospital in upstate NY who has been doing the research for like 5 years... I asked somebody to enquire about this and he said he would get back to me. Normally he is very prompt. The fact he has not heard back from Greg on this could be very telling. This would be multiple billions if very efficacious. Short position will be covering from the #$%$ moon.
your still hangin on in here, continuing to show what a complete fool you are ? HAW !
Is that all? Gosh, that'll hardly last them a year! I don't know if that even includes the 1,785,714 shares registered for the "equity incentive plan":
"Represents additional shares of Omeros Corporation (the “Registrant”) common stock, par value $0.01 per share (the “Common Stock”), available for issuance under the 2008 Equity Incentive Plan as a result of provisions in that plan that allow for automatic annual increases of the number of shares of Common Stock available for issuance. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Common Stock that become issuable under the 2008 Equity Incentive Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant’s outstanding shares of Common Stock."
And isn't that "automatic annual increases" just sooooooooooooo considerate of them too! HAW!!!!
I agree, but when there are these drops, I get a real bad feeling about things.
I had a few bios, and took a severe beating. The only one that held up OK is LGND, off about 4-5% from it's "median high" over the last week or so. Others got plastered.
LGND shd be a $150 stock this yr, and OMER shd be 20+. If the news on 721 is good, maybe 25.
But time will tell...I expect that the people who are selling ALXN will, at some point, be buying OMER.
Plus, ALXN does not get 550K/yr, that's a list price, they yield about 400K in the US, and less elsewhere. They do a lot of business outside the US. ALXN was a very big holding for me, yrs ago.
A better drug shd not be a less expensive drug...so let's hope that things progress well.
Penny.... My best guess is word is out on OMS721 , it's better no side effects like Sorilis. Also the cost is $550,000 per year . With the current political nosence and the call for lower drug pricing has put a world of hurt on ALXN and many other great drug co. It is my belief OMER has a great pipeline and we longs will be rewarded in time and the time is closing in our favor . We have good management, enough money, and a sold drug in Omidria to give us the money to move forward with out duliting our shares. This company is a winner!
Sentiment: Strong Buy
Just a thot to keep me from dying from anxiety over all this selling.
Since it has become clear that OMER will challenge ALXN's Soliris in future years, ALXN has shed billions of mkt cap.
But OMER is being sold off.
One or the other, pls. And I don't have any ALXN.
I think they have tabled OMS405 - they are focused on bringing OMS527 (PDE10) to the clinic. The last few presentations they haven't even mentioned 405, but have talked up 527 of having the potential to combat all kinds of addiction and compulsive disorders.
from the 10k, page 10. we know about the two patients with aHUS, but the latter part of the HSCT patients, is a first for me. (I hate reading the 10k for information, boring)
"The high-dose cohort enrolled two aHUS patients. One was plasma therapy-resistant with additional complicating disorders including hepatitis C, cryoglobulinemia and lymphoma. Prior to OMS721 treatment, the patient required repeated dialysis. Throughout treatment and through follow-up, the patient remained off dialysis. Hematological and renal parameters showed substantial improvement. The other patient was plasma therapy-responsive. She required plasma therapy twice weekly. The patient’s aHUS flared when she attempted to decrease her plasma therapy to once weekly. Following treatment with OMS721, the patient’s aHUS remitted and she has remained stable on plasma therapy once weekly. Two patients with HSCT-related TMA were enrolled in the high-dose cohort of Stage 1 of the Phase 2 clinical trial. One patient has a history of lymphoma and underwent HSCT complicated by a number of life-threatening disorders, including TMA. The patient showed significant improvement in TMA disease markers following OMS721 treatment. One other patient with HSCT-associated TMA enrolled in the high-dose cohort of Stage 1. This patient enrolled in the trial when his renal function had severely deteriorated. He discontinued the study early when no improvement in disease markers was observed."